This prospective case-control study aimed to assess the prevalence of hyperhomocysteinemia and explore its potential correlation with microangiopathic complications, specifically nephropathy and neuropathy, in a cohort of both type 1 and type 2 diabetic patients. Conducted at the Marc Sankalé Center of Abass Ndao Hospital in Dakar from June to September 2018, the study enrolled a total of 106 diabetic patients, comprising 93 type 2 diabetics and 13 type 1 diabetics, who were matched with control subjects free from clinically detectable pathologies, based on sex and age ± 2 years. The mean age of type 1 and type 2 diabetic patients was 24.46 ± 8.41 years and 57.28 ± 11.28 years, respectively. Our findings revealed a statistically significant elevation in mean homocysteine levels among patients when compared to controls (12.63 vs. 9.88; p < 0.0001). Hyperhomocysteinemia was observed in 24.5% of the patients, exclusively among those with type 2 diabetes. Within the hyperhomocysteinemia subgroup, 58% were male, and 42% were female. The analysis of neuropathy and nephropathy frequencies among type 2 diabetic patients, stratified by homocysteine concentrations, demonstrated a notably higher prevalence of diabetic nephropathy in patients with hyperhomocysteinemia compared to those with normohomocysteinemia (23.07% vs. 8.75%; p = 0.052). Similarly, diabetic neuropathy exhibited a significantly greater frequency in patients with hyperhomocysteinemia as opposed to normohomocysteinemia (80.76% vs. 50%; p = 0.005). Furthermore, our results established a significant positive correlation between homocysteine concentrations and both age (r = 0.402; p < 0.0001) and creatinine levels (r = 0.461; p < 0.0001). Bivariate logistic regression analysis indicated that patients with hyperhomocysteinemia faced 3 times and 6 times higher risks of developing neuropathy (OR = 3.5; p = 0.061) and diabetic nephropathy (OR = 6.092; p = 0.014), respectively.
References
[1]
Hong, S., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article ID: 109119. https://doi.org/10.1016/j.diabres.2021.109119
[2]
Shaikh, M.K., Devrajani, B.R., Shaikh, A., Shah, S.Z.A., Shaikh, S. and Singh, D. (2012) Plasma homocysteine Level in Patients with Diabetes Mellitus. World Applied Sciences Journal, 16, 1269-1273.
[3]
Bourbia, A., Moussi, S. and Derai, E.E. (2013) Hyperhomocystéinémie et néphropathie diabétique: rôle de quelques déterminants vitaminiques. Master’s Thesis, Université de Jijel, Jijel. http://dspace.univ-jijel.dz:8080/xmlui/handle/123456789/4323
[4]
Cohen, J.A., Jeffers, B.W., Stabler, S., Schrier, R.W. and Estascio, R. (2001) Increasing Homocysteine Levels and Diabetic Autonomic Neuropathy. Autonomic Neuroscience, 87, 268-273. https://doi.org/10.1016/S1566-0702(00)00262-9
[5]
Luo, J.J., Sivaraaman, K., Nouh, A. and Dun, N.J. (2014) Elevated Plasma Level of Homocysteine Is an Independent Risk Factor for Peripheral Neuropathy. Journal of Advances in Medicine and Medical Research, 4, 161-169. https://doi.org/10.9734/BJMMR/2014/5206
[6]
Muzurović, E., Kraljević, I., Solak, M., Dragnić, S. and Mikhailidis, D.P. (2020) Homocysteine and Diabetes: Role in Macrovascular and Microvascular Complications. Journal of Diabetes and Its Complications, 35, Article ID: 107834. https://doi.org/10.1016/j.jdiacomp.2020.107834
[7]
Ozmen, B., Ozmen, D., Turgan, N., Habif, S., Mutaf, I. and Bayindir, O. (2002) Association between Homocysteinemia and Renal Function in Patients with Type 2 Diabetes Mellitus. Annals of Clinical & Laboratory Science, 32, 279-286.
[8]
Ambrosch, A., Dierkes, J., Lobmann, R., Kühne, W., König, W., Luley, C., et al. (2001) Relation between Homocysteinaemia and Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus. Diabetic Medicine, 18, 185-192. https://doi.org/10.1046/j.1464-5491.2001.00445.x
[9]
Wijekoon, E.P., Brosnan, M.E. and Brosnan, J.T. (2007) Homocysteine Metabolism in Diabetes. Biochemical Society Transactions, 35, 1175-1179. https://doi.org/10.1042/BST0351175
[10]
Ndrepepa, G., Kastrati, A., Braun, S., Koch, W., Kölling, K., Mehilli, J., et al. (2008) Circulating Homocysteine Levels in Patients with Type 2 Diabetes Mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 18, 66-73. https://doi.org/10.1016/j.numecd.2006.03.007
[11]
Karabag, T., Kaya, A., Temizhan, A., Koç, F., Yavuz, S. and Cam, S. (2007) The Influence of Homocysteine Levels on Endothelial Function and Their Relation with Microvascular Complications in T2DM Patients without Macrovascular Disease. Acta Diabetologica, 44, 69-75. https://doi.org/10.1007/s00592-007-0245-7
[12]
Agardh, C.D., Agardh, E., Andersson, A. and Hultberg, B. (1994) Lack of Association between Plasma Homocysteine Levels and Microangiopathy in Type 1 Diabetes Mellitus. Scandinavian Journal of Clinical and Laboratory Investigation, 54, 637-641. https://doi.org/10.3109/00365519409087544
[13]
Pavia, C., Ferrer, I., Valls, C., Artuch, R., Colomé, C. and Vilaseca, M.A. (2000) Total Homocysteine in Patients with Type 1 Diabetes. Diabetes Care, 23, 84-87. https://doi.org/10.2337/diacare.23.1.84
[14]
Targher, G., Bertolini, L., Zenari, L., Cacciatori, V., Muggeo, M., Faccini, G., et al. (2000) Cigarette Smoking and Plasma Total Homocysteine Levels in Young Adults with Type 1 Diabetes. Diabetes Care, 23, 524-528. https://doi.org/10.2337/diacare.23.4.524
[15]
Emoto, M., Kanda, H., Shoji, T., Kawagishi, T., Komatsu, M., Mori, K., et al. (2001) Impact of Insulin Resistance and Nephropathy on Homocysteine in Type 2 Diabetes. Diabetes Care, 24, 533-538. https://doi.org/10.2337/diacare.24.3.533
[16]
Lanfredini, M., Fiorina, P., Peca, M.G., Veronelli, A., Mello, A., Astorri, E., et al. (1998) Fasting and Post—Methionine Load Homocyst(e)ine Values Are Correlated with Microalbuminuria and Could Contribute to Worsening Vascular Damage in Non—Insulin-Dependent Diabetes Mellitus Patients. Metabolism, 47, 915-921. https://doi.org/10.1016/S0026-0495(98)90344-4
[17]
Davies, L., Wilmshurst, E.G., McElduff, A., Gunton, J., Clifton-Bligh, P. and Fulcher, G.R. (2001) The Relationship among Homocysteine, Creatinine Clearance, and Albuminuria in Patients with Type 2 Diabetes. Diabetes Care, 24, 1805-1809. https://doi.org/10.2337/diacare.24.10.1805
[18]
Wirta, O.R., Pasternack, A.I., Oksa, H.H., Mustonen, J.T., Koivula, T.A., Helin, H.J., et al. (1995) Occurrence of Late Specific Complications in Type II (Non-Insulin-Dependent) Diabetes Mellitus. Journal of Diabetes and Its Complications, 9, 177-185. https://doi.org/10.1016/1056-8727(94)00034-L
[19]
Vinik, A.I. (2008) Diabetic Neuropathies. In: LeRoith, D. and Vinik, A.I., Eds., Controversies in Treating Diabetes, Humana Press, Totowa, 135-156. https://doi.org/10.1007/978-1-59745-572-5_8
[20]
Heydari-Zarnagh, H., Nejat, S.A. and Nourozi, A. (2014) Effect of Glycemic Control on Homocysteine Levels in Type 2 Diabetic Patients without Cardiovascular Disease. Zahedan Journal of Research in Medical Sciences, 16, 23-27.
[21]
Al-Attas, O.S., Al-Daghri, N.M. and Appiedu, G.A. (2009) Fasting Homocysteine Levels in a Cross-Section of Saudi Adults with Type 1 Diabetes Mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 3, 45-49. https://doi.org/10.1016/j.dsx.2008.10.009
[22]
Chico, A., Perez, A., Cordoba, A., Arcelus, R., Carreras, G., De Leiva, A., et al. (1998) Plasma Homocysteine Is Related to Albumin Excretion Rate in Patients with Diabetes Mellitus: A New Link between Diabetic Nephropathy and Cardiovascular Disease? Diabetologia, 41, 684-693. https://doi.org/10.1007/s001250050969
[23]
Robillon, J.F., Canivet, B., Candito, M., Sadoul, J.L., Jullien, D., Morand, P., et al. (1994) Type 1 Diabetes Mellitus and Homocysteine. Diabetes & Metabolism, 20, 494-496.
[24]
Wiltshire, E., Thomas, D.W., Baghurst, P. and Couper, J. (2001) Reduced Total Plasma Homocysteine in Children and Adolescents with Type 1 Diabetes. The Journal of Pediatrics, 138, 888-893. https://doi.org/10.1067/mpd.2001.113708
[25]
Cotellessa, M., Minniti, G., Cerone, R., Prigione, F., Calevo, M.G. and Lorini, R. (2001) Low Total Plasma Homocysteine Concentrations in Patients with Type 1 Diabetes. Diabetes Care, 24, 969-970. https://doi.org/10.2337/diacare.24.5.969
[26]
Hoogeveen, E.K., Kostense, P.J., Jakobs, C., Dekker, J.M., Nijpels, G., Heine, R.J., et al. (2000) Hyperhomocysteinemia Increases Risk of Death, Especially in Type 2 Diabetes. Circulation, 101, 1506-1511. https://doi.org/10.1161/01.CIR.101.13.1506
[27]
Buysschaert, M., Preumont, V. and Maiter, D. (2021) L’insulinothérapie en 2021. Louvain Médical, 140, 2-7.
[28]
Oh, E.S., Steele, C.N., You, Z., Nowak, K.L. and Jovanovich, A.J. (2022) Sex Hormones and the Risk of Cardiovascular Disease and Mortality in Male and Female Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Physiological Reports, 10, e15490. https://doi.org/10.14814/phy2.15490
[29]
Bruce, S.G. and Young, T.K. (2008) Prevalence and Risk Factors for Neuropathy in a Canadian First Nation Community. Diabetes Care, 31, 1837-1841. https://doi.org/10.2337/dc08-0278
[30]
Norlund, L., Grubb, A., Fex, G., Leksell, H., Nilsson, J.E., Schenck, H., et al. (1998) The Increase of Plasma Homocysteine Concentrations with Age Is Partly Due to the Deterioration of Renal Function as Determined by Plasma Cystatin C. Clinical Chemistry and Laboratory Medicine (CCLM), 36, 175-178. https://doi.org/10.1515/CCLM.1998.032
[31]
Andersson, A., Brattström, L., Israelsson, B., Isaksson, A., Hamfelt, A. and Hultberg, B. (1992) Plasma Homocysteine before and after Methionine Loading with Regard to Age, Gender, and Menopausal Status. European Journal of Clinical Investigation, 22, 79-87. https://doi.org/10.1111/j.1365-2362.1992.tb01940.x
[32]
Hofmann, M.A., Kohl, B., Zumbach, M.S., et al. (1998) Hyperhomocyst(e)inemia and Endothelial Dysfunction in IDDM. Diabetes Care, 21, 841-848. https://care.diabetesjournals.org/content/21/5/841.short
[33]
Munshi, M.N., Stone, A., Fink, L. and Fonseca, V. (1996) Hyperhomocysteinemia Following a Methionine Load in Patients with Non-Insulin-Dependent Diabetes Mellitus and Macrovascular Disease. Metabolism, 45, 133-135. https://doi.org/10.1016/S0026-0495(96)90211-5
[34]
Smulders, Y.M., Rakic, M., Slaats, E.H., Treskes, M., Sijbrands, E.J., Odekerken, D.A., et al. (1999) Fasting and Post-Methionine Homocysteine Levels in NIDDM. Determinants and Correlations with Retinopathy, Albuminuria, and Cardiovascular Disease. Diabetes Care, 22, 125-132. https://doi.org/10.2337/diacare.22.1.125
[35]
Wollesen, F., Brattström, L., Refsum, H., Ueland, P., Berglund, L. and Berne, C. (1999) Plasma Total Homocysteine and Cysteine in Relation to Glomerular Filtration Rate in Diabetes Mellitus. Kidney International, 55, 1028-1035. https://doi.org/10.1046/j.1523-1755.1999.0550031028.x
[36]
Welch, G.N. and Losealzo, J. (1998) Endothelial Cell Injury Due to Coppercatalyzed Hydrogen Peroxide Frome Homocysteine. The New England Journal of Medicine, 338, 1042-1050. https://doi.org/10.1056/NEJM199804093381507
[37]
Li, Y., Zhang, H., Jiang, C., Xu, M., Pang, Y., Feng, J., et al. (2013) Hyperhomocysteinemia Promotes Insulin Resistance by Inducing Endoplasmic Reticulum Stress in Adipose Tissue. Journal of Biological Chemistry, 288, 9583-9592. https://doi.org/10.1074/jbc.M112.431627
[38]
Mao, S., Xiang, W., Huang, S. and Zhang, A. (2014) Association between Homocysteine Status and the Risk of Nephropathy in Type 2 Diabetes Mellitus. Clinica Chimica Acta, 431, 206-210. https://doi.org/10.1016/j.cca.2014.02.007
[39]
Wada, J. and Makino, H. (2013) Inflammation and the Pathogenesis of Diabetic Nephropathy. Clinical Science, 124, 139-152. https://doi.org/10.1042/CS20120198
[40]
Stehouwer, C.D., Gall, M.A., Hougaard, P., Jakobs, C. and Parving, H.H. (1999) Plasma Homocysteine Concentration Predicts Mortality in Non-Insulin-Dependent Diabetic Patients with and without Albuminuria. Kidney International, 55, 308-314. https://doi.org/10.1046/j.1523-1755.1999.00256.x
[41]
Yu, X., Huang, Y.G., Hu, Q. and Ma, L.Q. (2009) Hyperhomocysteinemia Stimulates Hepatic Glucose Output and PEPCK Expression. Acta Biochimica et Biophysica Sinica, 41, 1027-1032. https://academic.oup.com/abbs/article/41/12/1027/761
